Sponsored by
The Alliance A071401 trial tested abemaciclib, an oral CDK4/6 inhibitor already approved for certain breast cancers, in patients with grade 2 or 3 recurrent or progressive meningiomas whose tumors carried NF2 or CDK pathway mutations. All patients had already been treated with surgery, radiation, or both, and had no standard treatment options remaining.
In this study, the first 24 treated patients received a median of nine cycles of abemaciclib. At six months, 58% of patients had no tumor progression, a good result when compared with prior studies showing only 0–29% of patients typically remained progression-free at that time point. Median progression-free survival was 10 months, and median overall survival was 29 months. These outcomes suggest meaningful disease stabilization in a population with very limited alternatives.